BridgeBio Pharma (BBIO) Change in Accured Expenses (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Change in Accured Expenses data on file, last reported at $4.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 56.77% year-over-year to $4.6 million; the trailing twelve-month figure through Mar 2026 stood at $79.5 million (up 275.15% YoY), and the FY2025 full-year result was $77.8 million, up 358.08% from the prior year.
• Change in Accured Expenses eased to $4.6 million in Q1 2026, from $74.6 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $74.6 million in Q4 2025 to a low of -$18.6 million in Q2 2025.
• A 5-year average of $6.2 million and a median of $1.8 million in 2024 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 967.33% in 2025, while the deepest fall reached 160.91% in 2025.
• Tracing BBIO's Change in Accured Expenses over 5 years: stood at -$3.6 million in 2022, then jumped by 431.89% to $12.0 million in 2023, then surged by 97.34% to $23.6 million in 2024, then surged by 216.12% to $74.6 million in 2025, then tumbled by 93.81% to $4.6 million in 2026.
• Business Quant data shows BBIO's Change in Accured Expenses at $4.6 million in Q1 2026, $74.6 million in Q4 2025, and $18.8 million in Q3 2025.